Steve Bryson, PhD, science writer —

Treatment for two years with oral ALZ-801 (valiltramiprosate) sustained cognition and lowered levels of disease-related biomarkers in people with early Alzheimer’s disease carrying one or two copies of the disease-linked APOE4 genetic variant. These are the top-line findings of an ongoing Phase 2 clinical trial (NCT04693520), whose…

Vaccine candidate UB-311 is safe, well tolerated, and triggered an antibody response against beta-amyloid in 93% of patients with mild Alzheimer’s disease, according to now published data from a Phase 2a trial. Immunization also led to nonsignificant trends in reducing beta-amyloid and slowing cognitive, functional, and dementia decline,…

Recruitment has begun for a Phase 2 clinical trial that’s evaluating Cognition Therapeutics’ once daily oral therapeutic candidate Elayta in adults with early Alzheimer’s disease. START (NCT05531656) expects to enroll about 540 adults, ages 50-85. The University of Kentucky Sanders-Brown Center on Aging (SBCoA) is the first to…

“Encouraging results” were reported in eight Alzheimer’s disease patients with dementia who were treated with COYA 301, an experimental therapy being evaluated in a small clinical trial, according to Coya Therapeutics, its developer. “Results of our open-label proof-of-concept study with COYA 301 in 8 patients with Alzheimer’s showed…

Nearly half of Alzheimer’s disease patients treated with TrueBinding’s investigational therapy TB006 for at least three months showed signs of disease reversal or cognitive improvement, according to data from an open-label extension (OLE) study. The findings expand on data from a completed Phase 2a trial (NCT05074498) that…

An innovation passport, the first step in the U.K.’s Innovative Licensing and Access Pathway (ILAP) — intended to accelerate the development and approval of new therapies that address an unmet medical need — has been awarded to AD04, ADvantage Therapeutics’ investigational immunotherapy for mild Alzheimer’s disease. The designation, granted…

DISCERN, a biomarker test reported to accurately diagnose Alzheimer’s disease at its earliest stages, routinely would be used by 90% of physicians who responded to a recent survey. With a positive test using a small skin sample, physicians were some six times more likely to diagnose Alzheimer’s and nearly three times…

Lecanemab (BAN2401), an amyloid-targeted antibody therapy for early Alzheimer’s disease, has been granted priority review in Japan, according to Eisai and Biogen, its developers. Priority review, as designated by the Japanese Ministry of Health, Labour and Welfare (MHLW), shortens the review period of applications seeking approval…

About 1.5 years of treatment with lecanemab (BAN2401) — now under regulatory review in the U.S. — was found to significantly slow the progression of dementia symptoms in people with early-onset Alzheimer’s disease. That’s according to just-released full data from the Phase 3 Clarity AD clinical trial, which showed…

The experimental therapy gantenerumab did not significantly slow clinical decline in people with early Alzheimer’s disease, failing to meet a primary trial goal, data from the Phase 3 GRADUATE 1 and 2 studies showed. Gantenerumab’s ability to remove beta-amyloid — the protein that forms plaques in patients’ brains…